Up Nearly 30% in August, Is SpaceX Stock Still a Buy?

SpaceX’s Q2 results drove a sharp rebound: revenue grew 92% YoY and net loss narrowed to $541M, alongside AI revenue rising from $818M to $2.56B and Starlink connectivity revenue increasing from $3.25B to $4.29B. Shares are up nearly 30% since Aug. 1 after insider lockup expiries, but the article flags a valuation overhang at ~41x sales on full-year revenue estimates. Netting strong operational momentum against expensive expectations, the takeaway is to stay patient until fundamentals catch up or the stock reprices.

Analysis

The market is implicitly paying a software-multiple for a business that is still mostly infrastructure-heavy and pre-true operating leverage. That sets up a fragile ownership base: momentum and growth funds can support the name while revenue is compounding fast, but once growth normalizes even modestly, a 40x+ sales asset can de-rate very quickly because there is little fundamental yield cushion.

The first-order unlock fear may be overstated; the more important second-order risk is that insider supply simply exposes how dependent the stock is on narrative rather than steady free-cash-flow conversion. If the next 1-2 quarters show any deceleration in the connectivity engine or a step-up in capex intensity, the market will likely reclassify SPCX from "AI adjacency" back to a capital-intensive network business, which should compress the multiple before any earnings damage shows up.

Contrarian view: the consensus may be underestimating how much cash and balance-sheet flexibility reduce left-tail risk, so a short based purely on lockup mechanics is weak. The cleaner bearish case is valuation plus narrative crowding; if investors can get the same AI exposure through NVDA or the same telecom beta through VZ/T at far less extreme multiples, SPCX needs a much stronger execution track record to justify retention. Over a 6-18 month horizon, the key falsifier is sustained growth above ~70% with losses narrowing faster than expected; absent that, the stock is more likely to grind lower than to compound from here.

Key Decisions for Investors

• Do not chase SPCX after the post-unlock squeeze; wait for either a 15-25% pullback or the next quarterly update before considering entry. Falsifier: two consecutive quarters of revenue growth staying above ~70% with no margin deterioration.
• If borrow/liquidity is workable, use a small tactical short in SPCX or a 1-3 month put spread into strength, targeting 15-20% downside from current levels. Stop if the stock holds above the recent post-IPO highs and management raises full-year guidance.
• Prefer NVDA over SPCX for AI exposure on a 3-6 month horizon; SPCX’s AI link is indirect and the valuation is doing the heavy lifting. This is a relative-value long NVDA / short SPCX expression, not a market hedge.
• Set an alert around the next lockup expiry window: if trading volume fades while price stays elevated, that is the best entry point for a bearish valuation trade. If volume expands without price break, the short thesis is weakening and should be reduced.